ProteinQure Inc.

Profile

ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. PQ203, its lead program is the first ever AI designed peptide in clinical trials. PQ203 is a peptide drug-conjugate for TOP1 resistant solid tumors and is in Phase I at the best hospitals in North America. Its platform has been validated (2+ development candidates) with four top 25 pharma companies in their experimental assays. ProteinQure also has exciting in-vivo POC for siRNA delivery to CNS and kidney.


Event details

Date: January 12 - 14, 2026

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

21 in total